Publications by authors named "P J Nowak"
SARS-CoV-2 was responsible for the global pandemic. Approximately 10-15% of patients with COVID-19 developed respiratory failure with adult acute respiratory distress syndrome (ARDS), which required treatment in the Intensive Care Unit (ICU). The cytokine storm observed in severe COVID-19 was frequently handled with steroids.
View Article and Find Full Text PDFOur study aimed to report on variables associated with communicative health literacy (COM-HL) in European adults. The HLS survey was conducted in 2019-2021 including nine countries which measured COM-HL by using a validated questionnaire (HLS-COM-P-Q6 with a score ranging from 0 to 100). Linear regression models were used to study variables associated with COM-HL globally (multilevel model with random intercepts and slopes and at country level) and in each country.
View Article and Find Full Text PDFThe work aimed to use and modify starch as a biodegradable and biocompatible polysaccharide to create a modern pH-sensitive anticancer drug carrier based on a hydrazone bond. The multi-step reaction created a material that can bind to the carbonyl group of anticancer drugs. Additionally, polysaccharide was used to coat magnetic nanoparticles to increase the applicability of the carrier system.
View Article and Find Full Text PDFTiO used for photocatalytic water purification is most active in the form of nanoparticles (NP), but their use is fraught with difficulties in separation from solution or/and a tendency to agglomerate. The novel materials designed in this work circumvent these problems by immobilizing TiO NPs on the surface of exfoliated clay minerals. A series of TiO/clay mineral composites were obtained using five different clay components: the Na-, CTA-, or H-form of montmorillonite (Mt) and Na- or CTA-form of laponite (Lap).
View Article and Find Full Text PDFArticle Synopsis
- Immunocompromised patients have shown weak responses to initial SARS-CoV-2 mRNA vaccinations, prompting recommendations for extra booster doses; however, real-world data on these recommendations is limited.
- A two-year follow-up of the COVAXID clinical trial involved 364 participants, focusing on their immune responses and the effects of their vaccination schedule and underlying health conditions.
- The study found that while some patients who initially had poor responses improved after additional doses, their immune response remained affected by their immunosuppressive status, emphasizing the need for ongoing vaccination efforts in these populations.